Bioray Biotech Statistics
Total Valuation
Bioray Biotech has a market cap or net worth of TWD 698.21 million. The enterprise value is 594.65 million.
| Market Cap | 698.21M |
| Enterprise Value | 594.65M |
Important Dates
The next estimated earnings date is Monday, April 20, 2026.
| Earnings Date | Apr 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioray Biotech has 29.59 million shares outstanding. The number of shares has decreased by -1.61% in one year.
| Current Share Class | 29.59M |
| Shares Outstanding | 29.59M |
| Shares Change (YoY) | -1.61% |
| Shares Change (QoQ) | -0.05% |
| Owned by Insiders (%) | 11.18% |
| Owned by Institutions (%) | n/a |
| Float | 13.95M |
Valuation Ratios
The trailing PE ratio is 23.01.
| PE Ratio | 23.01 |
| Forward PE | n/a |
| PS Ratio | 3.03 |
| PB Ratio | 1.59 |
| P/TBV Ratio | 1.59 |
| P/FCF Ratio | 22.34 |
| P/OCF Ratio | 20.82 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.10, with an EV/FCF ratio of 19.02.
| EV / Earnings | 19.50 |
| EV / Sales | 2.58 |
| EV / EBITDA | 10.10 |
| EV / EBIT | 16.74 |
| EV / FCF | 19.02 |
Financial Position
The company has a current ratio of 7.15, with a Debt / Equity ratio of 0.12.
| Current Ratio | 7.15 |
| Quick Ratio | 5.29 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.87 |
| Debt / FCF | 1.64 |
| Interest Coverage | 40.36 |
Financial Efficiency
Return on equity (ROE) is 7.12% and return on invested capital (ROIC) is 8.42%.
| Return on Equity (ROE) | 7.12% |
| Return on Assets (ROA) | 4.13% |
| Return on Invested Capital (ROIC) | 8.42% |
| Return on Capital Employed (ROCE) | 7.36% |
| Weighted Average Cost of Capital (WACC) | 5.80% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.43 |
| Inventory Turnover | 2.17 |
Taxes
In the past 12 months, Bioray Biotech has paid 7.73 million in taxes.
| Income Tax | 7.73M |
| Effective Tax Rate | 20.22% |
Stock Price Statistics
The stock price has decreased by -3.67% in the last 52 weeks. The beta is 0.34, so Bioray Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | -3.67% |
| 50-Day Moving Average | 22.81 |
| 200-Day Moving Average | 23.22 |
| Relative Strength Index (RSI) | 48.17 |
| Average Volume (20 Days) | 9,149 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bioray Biotech had revenue of TWD 230.06 million and earned 30.50 million in profits. Earnings per share was 1.03.
| Revenue | 230.06M |
| Gross Profit | 107.59M |
| Operating Income | 35.52M |
| Pretax Income | 38.23M |
| Net Income | 30.50M |
| EBITDA | 50.03M |
| EBIT | 35.52M |
| Earnings Per Share (EPS) | 1.03 |
Balance Sheet
The company has 154.87 million in cash and 51.32 million in debt, giving a net cash position of 103.56 million or 3.50 per share.
| Cash & Cash Equivalents | 154.87M |
| Total Debt | 51.32M |
| Net Cash | 103.56M |
| Net Cash Per Share | 3.50 |
| Equity (Book Value) | 439.96M |
| Book Value Per Share | 14.87 |
| Working Capital | 253.05M |
Cash Flow
In the last 12 months, operating cash flow was 33.54 million and capital expenditures -2.28 million, giving a free cash flow of 31.26 million.
| Operating Cash Flow | 33.54M |
| Capital Expenditures | -2.28M |
| Free Cash Flow | 31.26M |
| FCF Per Share | 1.06 |
Margins
Gross margin is 46.77%, with operating and profit margins of 15.44% and 13.26%.
| Gross Margin | 46.77% |
| Operating Margin | 15.44% |
| Pretax Margin | 16.62% |
| Profit Margin | 13.26% |
| EBITDA Margin | 21.75% |
| EBIT Margin | 15.44% |
| FCF Margin | 13.59% |
Dividends & Yields
Bioray Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.61% |
| Shareholder Yield | 1.61% |
| Earnings Yield | 4.37% |
| FCF Yield | 4.48% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Bioray Biotech has an Altman Z-Score of 6.24 and a Piotroski F-Score of 7.
| Altman Z-Score | 6.24 |
| Piotroski F-Score | 7 |